2025-08-11 - Analysis Report
Okay, here's an analysis of Johnson & Johnson (JNJ) based on the provided data, presented in English with simple numerical summaries and interpretations.

**Report: Johnson & Johnson (JNJ) Analysis**

**Company Overview:** Johnson & Johnson is a global healthcare company engaged in the research and development, manufacture, and sale of a broad range of products in the healthcare field.

**1. Performance vs. S&P 500 (VOO)**

*   **JNJ Cumulative Return:** 27.49%
*   **VOO Cumulative Return:** 84.01%
*   **Absolute Deviation:** -67.2% (JNJ underperformed VOO by 67.2% over the observed period)
*   **Relative Deviation:** 11.7 (JNJ's underperformance is in the 11.7th percentile of its historical deviation range).

**Analysis:** JNJ has significantly underperformed the S&P 500 (VOO) over the period examined. The relative deviation suggests that this underperformance is near the lower end of its historical range, indicating a potentially significant divergence.

**Alpha and Beta Analysis:**

| Year       | CAGR     | MDD     | Alpha   | Beta   | Cap(B) |
| ---------- | -------- | -------- | ------- | ------ | ------ |
| 2015-2017  | 28.0%   | 56.1%   | 26.0%   | 0.0    | 336.5  |
| 2016-2018  | 8.0%   | 56.6%   | 12.0%   | -0.0   | 310.8  |
| 2017-2019  | 18.0%   | 56.6%   | -5.0%   | 0.0    | 351.3  |
| 2018-2020  | 12.0%   | 59.2%   | -16.0%  | 0.0    | 379.0  |
| 2019-2021  | 32.0%   | 59.6%   | -17.0%  | 0.0    | 412.0  |
| 2020-2022  | 7.0%   | 61.4%   | 1.0%    | 0.0    | 425.4  |
| 2021-2023  | -15.0%  | 61.4%   | -35.0%  | 0.3    | 377.5  |
| 2022-2024  | -35.0%  | 61.4%   | -62.0%  | 0.2    | 348.3  |
| 2023-2025  | 0.0%   | 70.1%   | -49.0%  | 0.2    | 417.4  |

**Analysis:**

*   **CAGR (Compound Annual Growth Rate):** Fluctuating growth rates, with negative values in recent periods (2021-2025).
*   **MDD (Maximum Drawdown):** Consistently high drawdowns, indicating significant volatility and potential risk.
*   **Alpha:** Predominantly negative alpha values indicate underperformance relative to the market benchmark.
*   **Beta:** Beta values are generally low, suggesting low correlation with the market.
*   **Cap(B):** The market capitalization shows growth initially but declines in later periods.

**2. Recent Price Action**

*   **Current Price:** $173.33
*   **Last Market Data:** Price: $173.33, Previous Close: $171.53, Change: +1.05%
*   **5-day Moving Average:** 171.45
*   **20-day Moving Average:** 166.68
*   **60-day Moving Average:** 158.05

**Analysis:** The price is above all three moving averages, suggesting a short-term upward trend.  The recent change of 1.05% compared to the previous close indicates a positive movement, potentially a minor "bump" reflected the news.

**3. Market Risk Indicators & Expected Return**

*   **Market Risk Indicator (MRI):** 0.33 (Low Risk)
*   **RSI:** 69.26 (Approaching Overbought)
*   **PPO:** 0.14 (Positive Momentum)
*   **Hybrid Signal:** Buy 80% of cash (1 shares - Caution - MRI:0.34)
*   **Delta_Previous_Relative_Divergence:** +5.5 (Short-term Increase)
*   **Expected Return:** -226.6% (Significant Underperformance vs. S&P 500 Over 2+ Years)

**Analysis:**

*   The MRI suggests a low-risk environment.
*   The RSI is approaching overbought levels, indicating a potential pullback.
*   The PPO indicates positive momentum.
*   The significant negative expected return suggests caution regarding long-term relative performance.
*   The increase in "Delta_Previous_Relative_Divergence" confirms recent upward price movement.

**4. Recent News & Significant Events**

*   **[2025-08-07]:** Business developments, regulatory changes, or market events.
*   **[2025-08-10]:** Analyst discussions on performance and outlook.
*   **[2025-08-11]:** Stock volatility due to recent news.
*   **[2025-08-09]:** Experts highlight risks and opportunities, advising monitoring of news.

**Analysis:** Recent news suggests a dynamic environment with potential for both positive and negative impacts on the stock. The stock's volatility, coupled with analysts' risk/opportunity assessments, suggests caution.

**5. Recent Earnings Analysis**

| 날짜       | EPS  | 매출      |
| ---------- | ---- | --------- |
| 2025-07-24 | 2.3  | 23.74 B$  |
| 2025-04-23 | 4.57 | 21.89 B$  |
| 2024-10-23 | 1.12 | 22.47 B$  |
| 2024-07-25 | 1.95 | 22.45 B$  |
| 2025-07-24 | 1.95 | 22.45 B$  |

**Analysis:**

*   **EPS (Earnings Per Share):** EPS has fluctuated, with the most recent value at 2.3.
*   **Revenue:** Revenue also shows variation, peaking at $23.74B.

**6. Financial Information**

**Revenue and Profitability:**

| Quarter    | Revenue   | Profit Margin |
| ---------- | --------- | ------------- |
| 2025-06-30 | $23.74B   | 67.87%       |
| 2025-03-31 | $21.89B   | 66.40%       |
| 2024-12-31 | $22.52B   | 68.35%       |
| 2024-09-30 | $22.47B   | 69.01%       |
| 2024-06-30 | $22.45B   | 69.40%       |

**Capital and Profitability:**

| Quarter    | Equity    | ROE     |
| ---------- | --------- | ------- |
| 2025-06-30 | $78.47B   | 7.06%   |
| 2025-03-31 | $78.11B   | 14.08%  |
| 2024-12-31 | $71.49B   | 4.80%   |
| 2024-09-30 | $70.16B   | 3.84%   |
| 2024-06-30 | $71.54B   | 6.55%   |

**Analysis:**

*   **Revenue:** Relatively stable revenue stream.
*   **Profit Margin:** Consistently high profit margins.
*   **Equity:** Increasing equity.
*   **ROE (Return on Equity):** Fluctuating ROE.

**7. 종합 Analysis (Overall Summary)**

Johnson & Johnson (JNJ) exhibits a mixed picture:

*   **Underperformance:** Significant underperformance compared to the S&P 500, with negative expected returns relative to the index.
*   **Financial Strength:** Strong financials with consistent revenue and high-profit margins.
*   **Low Risk but Volatility:** MRI indicates low market risk.  However, the recent news indicates volatility.
*   **Mixed Signals:** Recent price action is positive, but the RSI is approaching overbought.
*   **Earnings:** Recent earnings are fluctuating.

**Conclusion:** JNJ appears to be a financially stable company, but it faces challenges in generating market-beating returns. Investors should be cautious due to the underperformance and recent volatility, carefully monitoring the news and analyst reports. A diversified portfolio may be a more prudent approach than over-weighting JNJ.
